InterCure Ltd
TASE:INCR
Net Margin
InterCure Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
IL |
I
|
InterCure Ltd
TASE:INCR
|
248.1m ILS |
-17%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
735.9B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
404B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
202.1B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
178.4B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
160.5B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
205.3B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
142.9B USD |
13%
|
InterCure Ltd
Glance View
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on InterCure Ltd's most recent financial statements, the company has Net Margin of -17.4%.